Last reviewed · How we verify
Intravenous omeprazole infusion
Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.
Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Acute gastric acid suppression in patients unable to take oral medication, Prevention and treatment of stress-related mucosal damage, Management of gastroesophageal reflux disease (GERD) in acute settings.
At a glance
| Generic name | Intravenous omeprazole infusion |
|---|---|
| Sponsor | Chinese University of Hong Kong |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Omeprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This results in sustained reduction of both basal and stimulated gastric acid secretion. The intravenous formulation allows for rapid onset and is used in acute settings where oral administration is not feasible.
Approved indications
- Acute gastric acid suppression in patients unable to take oral medication
- Prevention and treatment of stress-related mucosal damage
- Management of gastroesophageal reflux disease (GERD) in acute settings
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Hypomagnesemia (with chronic use)
Key clinical trials
- PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (PHASE4)
- A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis (PHASE1)
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (PHASE2)
- A Phase I Study of LX22001 for Injection in Healthy Subjects (PHASE1)
- A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease (PHASE1)
- LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (PHASE1)
- Esomeprazole to Reduce Organ Failure in Sepsis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous omeprazole infusion CI brief — competitive landscape report
- Intravenous omeprazole infusion updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI